Literature DB >> 18342817

Are there effective new strategies for the treatment of acute and chronic GvHD?

Nelson J Chao1.   

Abstract

The molecular biology and pathophysiology underlying graft-versus-host disease (GvHD) remains an area of intensive research. Understanding normal and abnormal developments of both the innate and adaptive immune systems are beginning to provide understanding of the details of relevant pathways. Recent work in gene-expression profiling suggests a critical next step in identifying broader patterns that will stand up to examination in independent data sets and provide a sturdy basis for targeted therapy and preventive measures against GvHD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342817      PMCID: PMC2329570          DOI: 10.1016/j.beha.2007.11.012

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  17 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy.

Authors:  G D Sempowski; L P Hale; J S Sundy; J M Massey; R A Koup; D C Douek; D D Patel; B F Haynes
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

3.  Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation.

Authors:  Benny J Chen; Xiuyu Cui; Gregory D Sempowski; Jos Domen; Nelson J Chao
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

4.  T-Cell recovery in adults and children following umbilical cord blood transplantation.

Authors:  A K Klein; D D Patel; M E Gooding; G D Sempowski; B J Chen; C Liu; J Kurtzberg; B F Haynes; N J Chao
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

5.  Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.

Authors:  David B Miklos; Haesook T Kim; Emmanuel Zorn; Ephraim P Hochberg; Luxuan Guo; Alex Mattes-Ritz; Sebastien Viatte; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

6.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease.

Authors:  Benny J Chen; Xiuyu Cui; Gregory D Sempowski; Congxiao Liu; Nelson J Chao
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

7.  Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation.

Authors:  Ernst Holler; Gerhard Rogler; Hans Herfarth; Julia Brenmoehl; Peter Johannes Wild; Joachim Hahn; Günther Eissner; Jürgen Schölmerich; Reinhard Andreesen
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

8.  MEK is a key modulator for TLR5-induced interleukin-8 and MIP3alpha gene expression in non-transformed human colonic epithelial cells.

Authors:  Sang Hoon Rhee; Andrew C Keates; Mary P Moyer; Charalabos Pothoulakis
Journal:  J Biol Chem       Date:  2004-04-06       Impact factor: 5.157

9.  Rituximab for steroid-refractory chronic graft-versus-host disease.

Authors:  Corey Cutler; David Miklos; Haesook T Kim; Nathaniel Treister; Sook-Bin Woo; Don Bienfang; Lloyd B Klickstein; Jesse Levin; Katherine Miller; Carol Reynolds; Rebecca Macdonell; Mildred Pasek; Stephanie J Lee; Vincent Ho; Robert Soiffer; Joseph H Antin; Jerome Ritz; Edwin Alyea
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

10.  Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation.

Authors:  Emmanuel Zorn; David B Miklos; Blair H Floyd; Alex Mattes-Ritz; Luxuan Guo; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  J Exp Med       Date:  2004-04-19       Impact factor: 14.307

View more
  4 in total

1.  Successful treatment using tacrolimus ointment for cutaneous graft-versus-host disease.

Authors:  Akane Kunitomi; Hiroatsu Iida; Yoshikazu Kamiya; Mayuko Hayashi; Hiroshi Sao
Journal:  Int J Hematol       Date:  2008-11-11       Impact factor: 2.490

Review 2.  DLL4+ dendritic cells: Key regulators of Notch Signaling in effector T cell responses.

Authors:  Lijun Meng; Shaoyan Hu; Jian Wang; Shan He; Yi Zhang
Journal:  Pharmacol Res       Date:  2016-09-14       Impact factor: 7.658

Review 3.  Notch and inflammatory T-cell response: new developments and challenges.

Authors:  Kazuhiro Mochizuki; Shan He; Yi Zhang
Journal:  Immunotherapy       Date:  2011-11       Impact factor: 4.196

4.  Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.

Authors:  Eric Bartee; Amy Meacham; Elizabeth Wise; Christopher R Cogle; Grant McFadden
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.